Alterity Therapeutics (ATH) H2 2025 earnings summary

Executive summary

• Achieved significant clinical milestones with ATH434, including completion of two Phase 2 trials in Multiple System Atrophy (MSA) showing statistically significant reduction in disease progression and favorable safety profile.

• ATH434 granted Fast Track designation by the FDA and Orphan Drug status in both the US and EU for MSA, highlighting regulatory recognition of unmet need and clinical benefit.

• Advanced biomarker innovation with the development of the MSA Atrophy Index (MSA-AI), enhancing diagnostic precision and disease tracking.

• Secured A$39.7 million in new funding, strengthening the cash position to A$33.2 million as of June 30, 2025.

Financial highlights

• Revenue from ordinary activities increased 66.3% year-over-year to A$446,291, primarily from interest income.

• Net loss after tax narrowed by 36.5% to A$12,147,828 compared to the prior year.

• Net tangible assets per share rose to 0.46 cents from 0.27 cents year-over-year.

• R&D expenses decreased 22.7% to A$14.4 million, reflecting the completion of certain studies.

• Cash and cash equivalents at year-end were A$33.2 million, up from A$12.6 million the previous year.

Outlook and guidance

• Sufficient cash runway for at least the next 12 months, with ongoing need for additional capital to support future R&D and commercialization.

• Focus remains on advancing ATH434 through late-stage clinical development and expanding the pipeline in neurodegenerative diseases.